DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0021786 A1 Schenkel Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0021786 A1 Schenkel Et Al US 2011 0021786A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0021786 A1 Schenkel et al. (43) Pub. Date: Jan. 27, 2011 (54) PHARMACEUTICAL SOLUTIONS, PROCESS (86). PCT No.: PCT/EP09/524.54 OF PREPARATION AND THERAPEUTC USES S371 (c)(1), (2), (4) Date: Oct. 6, 2010 (75) Inventors: Eric Schenkel, Brussels (BE): Claire Poulain, Brussels (BE); (30) Foreign Application Priority Data Bertrand Dodelet, Brussels (BE): Domenico Fanara, Brussels (BE) Mar. 3, 2008 (EP) .................................. O8OO3915.9 Correspondence Address: Publication Classification MCDONNELL BOEHNEN HULBERT & BERG HOFF LLP (51) Int. Cl. 300 S. WACKER DRIVE, 32ND FLOOR C07D 207/27 (2006.01) CHICAGO, IL 60606 (US) (52) U.S. Cl. ........................................................ 548/SSO (73) Assignee: UCB PHARMA, S.A., Brussels (BE) (57) ABSTRACT (21) Appl. No.: 12/920,524 The present invention concerns a stable pharmaceutical solu tion, a process of the preparation thereof and therapeutic uses (22) PCT Filed: Mar. 2, 2009 thereof. US 2011/002 1786 A1 Jan. 27, 2011 PHARMACEUTICAL SOLUTIONS, PROCESS 0006 Seletracetam is effective in the treatment of epi OF PREPARATION AND THERAPEUTC lepsy. USES 0007. Until now, brivaracetam and seletracetam have been formulated in Solid compositions (film coated tablet, gran ules). 0008. However, an oral solution would be particularly desirable for administration in children and also in some adult 0001. The present invention concerns stable liquid formu patients. An injectable Solution could be advantageously used lations of 2-oxo-1-pyrrolodine derivatives, a process of the in case of epilepsy crisis. preparation thereof and therapeutic uses thereof. 0009 Moreover, administration of an oral dosage form is 0002 International patent application having publication the preferred route of administration for many pharmaceuti number WO 01/62726 discloses 2-oxo-1-pyrrolidine deriva cals because it provides for easy, low-cost administration. tives and methods for their preparation. It particularly dis However some patients such as children or elderly people can have problems when requested to swallow a solid formulation closes compound (2S)-2-(4R)-2-oxo-4-propyl-pyrrolidin-1- Such as a tablet or a capsule. Hence the development of a ylbutanamide known under the international non propriety liquid oral formulation is therefore desirable since it offers name of brivaracetam. improved patient compliance. 0010. However, stability storage tests have shown that aqueous solutions of 2-oxo-1-pyrrolidine derivatives were partially unstable. During these tests, degradation products in Solution are formed by basic or acid hydrolysis, in fact an epimerisation and/oramide hydrolysis occurred, but also oxi dation, with detection of hydroxyamide and hydroxyacid impurities. CA, 0011. It has now surprisingly been found that these deg radation products are not formed at pH values between 4.5 and 6.5. In fact kinetics of degradation is the slowest in normal conditions (room temperature) when the drug solu n tion has a pH value of between 4.5 and 6.5. NH2 0012. The invention relates to a stable solution of a phar Brivaracetam maceutical compound, the solution having a pH value of between 4.5 and 6.5, and the pharmaceutical compound being an 2-oxo-1-pyrrolidine derivative of formula (I), 0003 International patent application having publication number WO 2005/121082 describes a process of preparation of 2-oxo-1-pyrrolidine derivatives and particularly discloses (I) a process of preparation of (2S)-2-(4S)-4-(2,2-difluorovi RI nyl)-2-oxo-pyrrolidin-1-ylbutanamide known under the s international non propriety name of seletracetam. 1s.N O 0013 wherein, I0014) R' is Co alkyl or C. alkenyl: 10015 R is Coalkyl or Coalkenyl: 0016 X is CONRR, COOH, -COORS or CN, 0017 R is Coalkyl: 10018) R' is hydrogen or Coalkyl: I0019 R is hydrogen or Co alkyl. 0020 Preferably, the solution of the invention has a pH Seletracetam values between 5.0 and 6.0. The best results are obtained with a pH value of about 5.5. 0004 2-oxo-1-pyrrolidine derivatives are therefore par 0021. By “stable' we mean optimum of stability in normal ticularly useful in the pharmaceutical industry. condition of storage (room temperature). 0022. The term “alkyl, as used herein, is a group which 0005 Brivaracetam is effective in the treatment of epi represents Saturated, monovalent hydrocarbon radicals hav lepsy. Brivaracetam is also effective in the treatment of ing straight (unbranched), branched or cyclic moieties, or patients with refractory partial onset seizures, with or without combinations thereof. Preferred alkyl comprises 1 to 10 car secondary generalization. In the therapeutic confirmatory bons. More preferred alkyl comprises 1 to 4 carbons. Option Phase III studies the efficacy and safety of brivaracetam are ally, alkyl groups may be substituted by 1 to 5 substituents tested at doses of 5 to 100 mg per day in the adjunctive independently selected from the group consisting of halogen, treatment of adult patients (16-65 years). Brivaracetam has hydroxy, alkoxy, ester, acyl, cyano, acyloxy, acid, amide or also an indication in the treatment of Progressive Myoclonic amino group. Preferred alkyl groups are methyl, ethyl, n-pro Epilepsy and of Symptomatic Myoclonus. pyl, trifluoromethyl and trifluoroethyl. US 2011/002 1786 A1 Jan. 27, 2011 0023 The term “alkenyl as used herein represents unsub R is a C- alkyl. In another embodiment according to first stituted or substituted branched, unbranched or cyclic hydro aspect of the present invention, X is COOR, wherein R is a carbon radicals or combinations thereof having at least one Calkyl. double bond. Preferred alkenyl comprises 2 to 6 carbons. I0041. In a particular embodiment, R is methyl. More preferred alkenyl comprises 2 to 4 carbons. “Alkenyl 0042. In one embodiment according to first aspect of the moieties may be optionally substituted by 1 to 5 substituents present invention, R is hydrogen or C. alkyl. In another independently selected from the group consisting of halogen, embodiment according to first aspect of the present invention, hydroxy, alkoxy, ester, acyl, cyano, acyloxy, carboxylic acid, R" is hydrogen. amide or amino group. 0043. In one embodiment according to first aspect of the 0024. The term “halogen', as used herein, represents an present invention, R is hydrogen or C. alkyl. In another atom of fluorine, chlorine, bromine, or iodine. embodiment according to the first aspect of the present inven 0025. The term “hydroxy’, as used herein, represents a tion, R is hydrogen. group of formula—OH. 0044 Preferably R' is n-propyl or 2,2-difluororovinyl: R 0026. The term “alkoxy’, as used herein, represents a is ethyl; and X is CONH2. group of formula —OR" wherein R is C alkyl as defined 0045. In particular, the invention relates to an injectable above. solution oran oral solution. When it is an injectable solution, 0027. The term “acyl as used herein, represents a group the solution has preferably a pH value of 5.5+0.2. When it is of formula RCO , wherein R represents a C, alkyl as an oral solution, the solution has preferably a pH value of defined above. 55.0.2. 0028. The term “ester', as used herein, represents a group 0046. The amount by weight of the pharmaceutical com of formula – COOR wherein R represents a C alkyl as pound in an injectable solution is generally in the range of defined above. 0.01 mg per ml to 200 mg per ml; and preferably of 0.1 mg to 0029. The term "cyano' as used herein represents a group 50 mg per ml; and more preferably of 1 mg to 30 mg per ml. of formula—CN. 0047. The amount by weight of the pharmaceutical com 0030 The term “acyloxy” as used herein represents a pound in an oral Solution is generally in the range of 0.01 mg group of formula—O COR", wherein R is a C, alkyl as per ml to 100 mg per ml; preferably of 0.1 mg to 50 mg perml; defined above or an aryl group. and more preferably of 1 mg to 20 mg per ml. 0031. The term “aryl” as used herein, represents an 0048. Usually, the solution is aqueous or alcoholic. In a organic radical derived from an aromatic hydrocarbon by preferred embodiment of the invention, the solution is an removal of one hydrogen, for example a phenyl. aqueous solution: water is used as solvent, preferably purified 0032. The term “carboxylic acid as used herein repre water for an oral aqueous solution and water for injection and sents a group of formula—COOH. pyrogen-free for the injectable form. 0033. The term “amino group', as used herein, represents 0049. The solution can be administered directly intrave a group of formula - NH, NHR or NRR where RandR nously, intramuscular or parenterally, or designed as infusion are alkyl groups as defined above in the specification. Solutions or concentrates as Supplements to infusions. 0034. The term "amide', as used herein, refers to a group 0050. Substances for adjusting the pH value are physi of formula CO. NH CO. NHRs, or CO NR'R'', ological buffers. The pH of the compositions is maintained by wherein R and R" are alkyl groups as defined above in the a buffer system. Buffer systems comprise mixtures of appro specification. priate amounts of an acid Such as phosphoric, succinic, tar taric, lactic, or citric acid, and a base, in particular sodium 0035. The term "sulfonate group’ as used herein repre hydroxide or disodium hydrogen phosphate. Ideally, the sents a group of formula – O SO. R' wherein R is an buffer has sufficient capacity to remain in the intended pH alkyl or an aryl as defined here above in the specification. range upon dilution with a neutral, a slightly acidic or a Preferred Sulfonate groups are methanesulfonate, para-tolu slightly basic beverage.
Load more

Recommended publications
  • Mechanisms of Action of Antiepileptic Drugs
    Review Mechanisms of action of antiepileptic drugs Epilepsy affects up to 1% of the general population and causes substantial disability. The management of seizures in patients with epilepsy relies heavily on antiepileptic drugs (AEDs). Phenobarbital, phenytoin, carbamazepine and valproic acid have been the primary medications used to treat epilepsy for several decades. Since 1993 several AEDs have been approved by the US FDA for use in epilepsy. The choice of the AED is based primarily on the seizure type, spectrum of clinical activity, side effect profile and patient characteristics such as age, comorbidities and concurrent medical treatments. Those AEDs with broad- spectrum activity are often found to exert an action at more than one molecular target. This article will review the proposed mechanisms of action of marketed AEDs in the US and discuss the future of AEDs in development. 1 KEYWORDS: AEDs anticonvulsant drugs antiepileptic drugs epilepsy Aaron M Cook mechanism of action seizures & Meriem K Bensalem-Owen† The therapeutic armamentarium for the treat- patients with refractory seizures. The aim of this 1UK HealthCare, 800 Rose St. H-109, ment of seizures has broadened significantly article is to discuss the past, present and future of Lexington, KY 40536-0293, USA †Author for correspondence: over the past decade [1]. Many of the newer AED pharmacology and mechanisms of action. College of Medicine, Department of anti epileptic drugs (AEDs) have clinical advan- Neurology, University of Kentucky, 800 Rose Street, Room L-455, tages over older, so-called ‘first-generation’ First-generation AEDs Lexington, KY 40536, USA AEDs in that they are more predictable in their Broadly, the mechanisms of action of AEDs can Tel.: +1 859 323 0229 Fax: +1 859 323 5943 dose–response profile and typically are associ- be categorized by their effects on the neuronal [email protected] ated with less drug–drug interactions.
    [Show full text]
  • PR2 2009.Vp:Corelventura
    Pharmacological Reports Copyright © 2009 2009, 61, 197216 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Review Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions Jarogniew J. £uszczki1,2 Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, PL 20-090 Lublin, Poland Department of Physiopathology, Institute of Agricultural Medicine, Jaczewskiego 2, PL 20-950 Lublin, Poland Correspondence: Jarogniew J. £uszczki, e-mail: [email protected]; [email protected] Abstract: This review briefly summarizes the information on the molecular mechanisms of action, pharmacokinetic profiles and drug interac- tions of novel (third-generation) antiepileptic drugs, including brivaracetam, carabersat, carisbamate, DP-valproic acid, eslicar- bazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, and valrocemide. These novel antiepileptic drugs undergo intensive clinical investigations to assess their efficacy and usefulness in the treatment of patients with refractory epilepsy. Key words: antiepileptic drugs, brivaracetam, carabersat, carisbamate, DP-valproic acid, drug interactions, eslicarbazepine, fluorofelbamate, fosphenytoin, ganaxolone, lacosamide, losigamone, pharmacokinetics, pregabalin, remacemide, retigabine, rufinamide, safinamide, seletracetam, soretolide, stiripentol, talampanel, valrocemide Abbreviations: 4-AP
    [Show full text]
  • Pharmaceutical Composition Comprising Brivaracetam and Lacosamide with Synergistic Anticonvulsant Effect
    (19) TZZ __T (11) EP 2 992 891 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.03.2016 Bulletin 2016/10 A61K 38/04 (2006.01) A61K 31/4015 (2006.01) A61P 25/08 (2006.01) (21) Application number: 15156237.8 (22) Date of filing: 15.06.2007 (84) Designated Contracting States: (71) Applicant: UCB Pharma GmbH AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 40789 Monheim (DE) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: STOEHR, Thomas 2400 Mol (BE) (30) Priority: 15.06.2006 US 813967 P 12.10.2006 EP 06021470 (74) Representative: Dressen, Frank 12.10.2006 EP 06021469 UCB Pharma GmbH 22.11.2006 EP 06024241 Alfred-Nobel-Strasse 10 40789 Monheim (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 07764676.8 / 2 037 965 This application was filed on 24-02-2015 as a divisional application to the application mentioned under INID code 62. (54) PHARMACEUTICALCOMPOSITION COMPRISING BRIVARACETAM AND LACOSAMIDE WITH SYNERGISTIC ANTICONVULSANT EFFECT (57) The present invention is directed to a pharmaceutical composition comprising (a) lacosamide and (b) brivara- cetam for the prevention, alleviation or/and treatment of epileptic seizures. EP 2 992 891 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 992 891 A1 Description [0001] The present application claims the priorities of US 60/813.967 of 15 June 2006, EP 06 021 470.7 of 12 October 2006, EP 06 021 469.9 of 12 October 2006, and EP 06 024 241.9 of 22 November 2006, which are included herein by 5 reference.
    [Show full text]
  • Antiepileptic Potential of Ganaxolone Antiepileptički Potencijal Ganaksolona
    Vojnosanit Pregl 2017; 74(5): 467–475. VOJNOSANITETSKI PREGLED Page 467 UDC: 615.03::616.853-085 GENERAL REVIEW https://doi.org/10.2298/VSP151221157J Antiepileptic potential of ganaxolone Antiepileptički potencijal ganaksolona Slobodan Janković, Snežana Lukić Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Key words: Ključne reči: ganaxolone; epilepsies, partial; neurotransmitter ganaksolon; epilepsije, parcijalne; neurotransmiteri; agents; child; adult. deca; odrasle osobe. Introduction New anticonvulsants With its estimated prevalence of 0.52% in Europe, The drug resistant epilepsy has been recently defined by 0.68% in the United States of America and up to 1.5% in de- the International League Against Epilepsy as “a failure of veloping countries, epilepsy makes a heavy burden on indi- adequate trials of two tolerated, appropriately chosen and viduals, healthcare systems and societies in general all over used antiepileptic drug schedules (whether as monotherapies the world 1, 2. Despite long history of epilepsy treatment with or in combination) to achieve sustained seizure free- dom” 11.The mechanisms of drug resistance in epilepsy are medication, efficacy and effectiveness of available antiepi- still incompletely understood, and none of the anticonvul- leptic drugs as monotherapy were unequivocally proven in sants with current marketing authorization has demonstrated clinical trials only for partial-onset seizures in children and superior efficacy in the treatment of drug resistant epilepsy 12. adults (including elderly), while generalized-onset tonic- Using new anticonvulsants as add-on therapy lead to free- clonic seizures in children and adults, juvenile myoclonic dom from seizures in only 6% of patients with drug resistant epilepsy and benign epilepsy with centrotemporal spikes are epilepsy 13.
    [Show full text]
  • Telemetric EEG and the Rat: a Guide for Neuroscientists
    Editorial Telemetric EEG and the Rat: A Guide For Neuroscientists Jafri Malin AbdullAh1, Mohammad RAfiqul islAm2 1 Malaysian Journal of Medical Sciences, Universiti Sains Malaysia Press, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia 2 Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia Abstract Telemetric EEG in the rat’s brain has been used for experiments which tests the effects of an antiepileptic compound on it’s antiseizures activity. A simple classification correlating epileptiform discharge and Racine’s behavioral activity is discussed. Keywords: electroencephalogram, neuroscience, rat, telemetry Animal models for seizures and epilepsy scale for the assessment of seizure intensities in have played a fundamental role in advancing our other epilepsy or seizure models is justifiable, understanding of basic mechanisms underlying given the well known relation between activated ictogenesis and epileptogenesis and have been brain part and corresponding expressed behavior instrumental in the discovery and preclinical of Sprague Dawley rats (160–350 g) which are development of novel antiepileptic drugs. suitable animals to induce status epilepticus Despite the successful development of various models and to record continuous EEG spikes and new antiepileptic drugs in recent decades, the wave discharges (4–6). search for new therapies with better efficacy and We used a total of 10 male Sprague Dawley tolerability remains an important goal (1). The and 6 Genetic Absence Epilepsy Rats from discovery and development of a new antiepileptic Strasbourg (GAERS) rats (7), four to six months drug relies heavily on the preclinical use of animal of age and weighing 187–325 g.
    [Show full text]
  • Brivaracetam and Perampanel As Broad-Spectrum Antiseizure Drugs
    Expert Opinion on Pharmacotherapy ISSN: 1465-6566 (Print) 1744-7666 (Online) Journal homepage: https://www.tandfonline.com/loi/ieop20 Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad- spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus Laurent Maximilian Willems, Sebastian Bauer, Felix Rosenow & Adam Strzelczyk To cite this article: Laurent Maximilian Willems, Sebastian Bauer, Felix Rosenow & Adam Strzelczyk (2019): Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2019.1637420 To link to this article: https://doi.org/10.1080/14656566.2019.1637420 Published online: 02 Jul 2019. Submit your article to this journal View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ieop20 EXPERT OPINION ON PHARMACOTHERAPY https://doi.org/10.1080/14656566.2019.1637420 REVIEW Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus Laurent Maximilian Willems a,b, Sebastian Bauera,b, Felix Rosenowa,b and Adam Strzelczyk a,b,c aEpilepsy Center Frankfurt Rhine-Main and Department of Neurology, Goethe-University Frankfurt, Frankfurt am Main, Germany; bLOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany; cEpilepsy Center Hessen and Department of Neurology, Philipps-University Marburg, Marburg (Lahn), Germany ABSTRACT ARTICLE HISTORY Introduction: Antiseizure drugs (ASDs) play a central and crucial role in the treatment of epilepsy Received 11 May 2019 patients, as the majority require anticonvulsant treatment for an extended period of time.
    [Show full text]
  • Levetiracetam Inhibits Endocytosis and Augments Short-Term Depression
    ORIGINAL ARTICLES Department of Physiology and Biophysics, School of Life Sciences, Fudan University, Shanghai, China Levetiracetam inhibits endocytosis and augments short-term depression LI-MENG, LEI-XUE* Received July 5, 2018, accepted August 5, 2018 *Corresponding author: Lei-Xue, Department of Physiology and Biophysics, School of Life Sciences, Fudan University, Shanghai, China, 200438 [email protected] Pharmazie 73: 643–646 (2018) doi: 10.1691/ph.2018.8634 Levetiracetam (LEV) is an anti-epileptic drug with demonstrated efficacy against generalized seizures. Recent studies have found that LEV affects the release of neurotransmitters by binding to synaptic vesicle protein 2A (SV2A). However, the details of LEV regulation of synaptic transmission remain poorly understood. Here, we used the whole-cell patch-clamp technique to further characterize the effects of LEV on synaptic transmission at a large mammalian central synapse, the calyx of Held. Our results showed that two common forms of vesicle endocytosis, including slow and rapid endocytosis, were dramatically inhibited when slices were incubated in 100 μM LEV for 1 h, however, the action potential (AP), calcium influx and exocytosis were not affected. Further- more, by measuring the level of steady-state depression induced by 100 Hz stimulus trains, we found that the steady state level of depression was significantly stronger after LEV treatment, indicating that LEV enhanced short-term depression (STD). Thus, these findings suggested that the mechanisms of the antiepileptic of LEV seem to be mediated, at least partly, by regulating endocytosis and STD. 1. Introduction neuronal activity indicated that interaction of LEV with SV2A is Epilepsy is a symptom due to abnormal excessive neuronal activity likely to explain the phenomenon.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Antiepileptic Potential of Ganaxolone Antiepileptički Potencijal Ganaksolona
    Vojnosanit Pregl 2017; 74(5): 467–475. VOJNOSANITETSKI PREGLED Page 467 UDC: 615.03::616.853-085 GENERAL REVIEW https://doi.org/10.2298/VSP151221157J Antiepileptic potential of ganaxolone Antiepileptički potencijal ganaksolona Slobodan Janković, Snežana Lukić Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Key words: Ključne reči: ganaxolone; epilepsies, partial; neurotransmitter ganaksolon; epilepsije, parcijalne; neurotransmiteri; agents; child; adult. deca; odrasle osobe. Introduction New anticonvulsants With its estimated prevalence of 0.52% in Europe, The drug resistant epilepsy has been recently defined by 0.68% in the United States of America and up to 1.5% in de- the International League Against Epilepsy as “a failure of veloping countries, epilepsy makes a heavy burden on indi- adequate trials of two tolerated, appropriately chosen and viduals, healthcare systems and societies in general all over used antiepileptic drug schedules (whether as monotherapies the world 1, 2. Despite long history of epilepsy treatment with or in combination) to achieve sustained seizure free- dom” 11.The mechanisms of drug resistance in epilepsy are medication, efficacy and effectiveness of available antiepi- still incompletely understood, and none of the anticonvul- leptic drugs as monotherapy were unequivocally proven in sants with current marketing authorization has demonstrated clinical trials only for partial-onset seizures in children and superior efficacy in the treatment of drug resistant epilepsy 12. adults (including elderly), while generalized-onset tonic- Using new anticonvulsants as add-on therapy lead to free- clonic seizures in children and adults, juvenile myoclonic dom from seizures in only 6% of patients with drug resistant epilepsy and benign epilepsy with centrotemporal spikes are epilepsy 13.
    [Show full text]
  • Synthesis and Discovery of the Putative Cognitive Enhancer BRS- 015: Effect on Glutamatergic Transmission and Synaptic Plasticity
    UCL SCHOOL OF PHARMACY BRUNSWICK SQUARE Synthesis and discovery of the putative cognitive enhancer BRS- 015: effect on glutamatergic transmission and synaptic plasticity Blanka Szulc Supervisors: Dr Stephen Hilton and Dr Arnaud Ruiz 29/07/2014 This research project is submitted in part fulfilment of the requirements for the PhD degree, UCL School of Pharmacy Department of Pharmaceutical and Biological Chemistry and the Pharmacology Department Blanka Szulc Discovery and mode of action of BRS-015 Abstract This thesis is concerned with the discovery of a novel heterocyclic compound – BRS-015, its synthesis and an analysis of its effects on excitatory synaptic transmission at a major pathway in the brain. BRS-015 is related to the natural product clausenamide, which has been shown to facilitate synaptic transmission. As such, clausenamide and related analogues may possess therapeutic potential as memory enhancing drugs, which are in urgent need of development due to the increasing numbers of patients diagnosed with memory disorders and for which there is no current effective therapy. BRS-015 was synthesized using a novel approach to the core structure of clausenamide involving an intramolecular acylal cyclisation reaction, which has not previously been reported. The first section of the thesis opens with a description of the discovery, structure and biological activity of clausenamide and discussion of previous synthetic strategies adopted by a number of research groups and attempts to classify these into the varying approaches towards the central core of clausenamide. The second section describes the structure of the rat brain and the types of processes involved in memory formation, as well as the neurophysiological assays used to investigate synaptic transmission and plasticity.
    [Show full text]
  • Seletracetam (UCB 44212)
    Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics Seletracetam (UCB 44212) Barbara Bennett,* Alain Matagne,† Philippe Michel,‡ Michèle Leonard,§ Miranda Cornet,§ Marie-Anne Meeus,¶ and Nathalie Toublanc¶ *CNS Clinical Development, UCB Atlanta, Smyrna, Georgia 30080; †Preclinical CNS, ‡Chemistry, §Non-clinical Development, and ¶Clinical Pharmacology, UCB Braine-l’Alleud, Belgium Summary: Better pharmacotherapies for epilepsy are needed demonstrates low plasma protein binding (Ͻ10%), which sug- for patients who are refractory to or have tolerability difficulties gests a low potential for drug–drug interactions. Initial studies with current treatments. Seletracetam, a new drug in epilepsy in humans demonstrated first-order monocompartmental kinet- development, is a pyrrolidone derivative structurally related to ics with a half-life of 8 h and an oral bioavailability of Ͼ90%. levetiracetam (trade name Keppra). It was discovered because Studies in healthy volunteers showed that the treatment emer- of its high binding affinity to the synaptic vesicle 2A (SV2A) gent adverse events were of mild to moderate severity, were protein, which is now known to be the binding site for this mostly of CNS origin and were resolved within 24 h. Alto- family of compounds. Seletracetam shows very potent seizure gether, these results suggest that seletracetam represents a suppression in models of acquired or genetic epilepsy, as well promising new antiepileptic drug candidate, one that demon- as high CNS tolerability in various animal models. Pharmaco- strates a potent, broad spectrum of seizure protection and a high kinetic studies in animals suggest that seletracetam is rapidly CNS tolerability in animal models, with initial clinical findings and highly absorbed, with linear and time-independent phar- suggestive of straightforward pharmacokinetics and good tol- macokinetics.
    [Show full text]
  • Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
    Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Related Titles Smith, D. A., Allerton, C., Kalgutkar, A. S., Curry, S. H., Whelpton, R. van de Waterbeemd, H., Walker, D. K. Drug Disposition and Pharmacokinetics and Metabolism Pharmacokinetics in Drug Design From Principles to Applications 2012 2011 ISBN: 978-3-527-32954-0 ISBN: 978-0-470-68446-7 Gad, S. C. (ed.) Rankovic, Z., Morphy, R. Development of Therapeutic Lead Generation Approaches Agents Handbook in Drug Discovery 2012 2010 ISBN: 978-0-471-21385-7 ISBN: 978-0-470-25761-6 Tsaioun, K., Kates, S. A. (eds.) Han, C., Davis, C. B., Wang, B. (eds.) ADMET for Medicinal Chemists Evaluation of Drug Candidates A Practical Guide for Preclinical Development 2011 Pharmacokinetics, Metabolism, ISBN: 978-0-470-48407-4 Pharmaceutics, and Toxicology 2010 ISBN: 978-0-470-04491-9 Sotriffer, C. (ed.) Virtual Screening Principles, Challenges, and Practical Faller, B., Urban, L. (eds.) Guidelines Hit and Lead Profiling 2011 Identification and Optimization ISBN: 978-3-527-32636-5 of Drug-like Molecules 2009 ISBN: 978-3-527-32331-9 Florencio Zaragoza Dorwald¨ Lead Optimization for Medicinal Chemists Pharmacokinetic Properties of Functional Groups and Organic Compounds The Author All books published by Wiley-VCH are carefully produced. Nevertheless, authors, Dr. Florencio Zaragoza D¨orwald editors, and publisher do not warrant the Lonza AG information contained in these books, Rottenstrasse 6 including this book, to be free of errors. 3930 Visp Readers are advised to keep in mind that Switzerland statements, data, illustrations, procedural details or other items may inadvertently be Cover illustration: inaccurate.
    [Show full text]